articles This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Article 3 months ago - 10 mins read Drug Discovery Technology Review: Emerging Tools and Modalities in 2022Q1 We did a comprehensive review of industry news in 2022Q1 (there was.. a lot of stuff to cover). In this article, we highlight some emerging companies, technologies, and drug discovery modalities we thought drug hunters would find interesting, including: New platform companies focused on drug discoveryDifferent approaches to glues and degradersStrategies for targeting DNA, RNA,… Article 3 months ago - 5 mins read Production-Scale Synthesis of gem-Dimethylcyclopropylproline The gem-dimethylcyclopropyl group is a key element in drugs, candidates, and agrochemicals, with a recent example being nirmatrelvir, the active ingredient in the Pfizer COVID-19 drug, Paxlovid. Here, we review synthetic strategies used to produce the key gem-dimethylcyclopropylproline intermediate, which may now be required in hundred-ton quantities to support nirmatrelvir manufacturing. Synthesis Spotlight: The gem-Dimethylcyclopropyl… Article 3 months ago - 4 mins read Drug Discovery IPOs in 2022Q1 We did a comprehensive review of industry news in 2022Q1 (there was.. a lot of stuff to cover). This article highlights companies focused on drug discovery that IPO’d in the first quarter. The Drug Discovery IPO Market Slowdown As everyone knows, biotech’s been in a bear market since Feb. 2021 (with the entire $XBI index… Article 3 months ago - 12 mins read Review of 2021 FDA-Approved Drugs for Genetic Conditions The FDA approved five new drugs in 2021 for use for genetic conditions, including molybdenum cofactor deficiency, Von Hippel-Lindau (VHL) disease, achondroplasia, and progressive familial intrahepatic cholestasis (PFIC). This article and slide deck reviews each in detail, including their mechanisms of action, originators, key clinical data, disease context, target rationale, and more… Article 3 months ago - 9 mins read FDA Novel Drug Approvals: April 2022 There were two novel small molecules approved in April 2022: mavacamten (Camzyos), an oral cardiac myosin inhibitor oteseconazole (Vivjoy), an oral antifungal (jump to section) This deep dive explores each drug in more detail, including the industry context, the clinical data, the target rationale, mechanisms of action, and drug origins. Article 3 months ago - 4 mins read Drug Hunter Letters #2: On Carboxylic Acids and Acylglucuronides Recently, Dr. Alf Claesson (CEO of Awametox AB, inventor of SpotRM, and previously Principal Scientist and Section Head at AstraZeneca/Astra AB, Sweden) reached out about our resource on the bioactivation of structural alerts. Dr. Claesson shared the helpful notes that: carboxylic acids forming thioesters with CoA might be a greater danger than those forming acyl… Pages: 1234567891011121314Load More
